Insiders · FULC

FULC insider transactions

Fulcrum Therapeutics Inc. (FULC) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for FULC

• 85d
  Amendment: Director Gould Robert J sold $163,089 worth of shares (15,000 units at $10.87), decreasing direct ownership by 3% to 469,864 units (SEC Form 4)

  4/A - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 85d
  SEC Form 4 filed by Chief Financial Officer Musso Alan A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 85d
  SEC Form 4 filed by Principal Accounting Officer Tourangeau Greg

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 85d
  SEC Form 4 filed by Chief Legal Officer Oltmans Curtis Gale

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 85d
  Director Gould Robert J sold $160,857 worth of shares (15,000 units at $10.72), decreasing direct ownership by 3% to 454,864 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 85d
  SEC Form 4 filed by Officer Sapir Alex

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 114d
  Director Gould Robert J sold $178,089 worth of shares (15,000 units at $11.87), decreasing direct ownership by 3% to 469,864 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 134d
  Chief Legal Officer Oltmans Curtis Gale sold $44,600 worth of shares (3,452 units at $12.92), decreasing direct ownership by 25% to 10,252 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 141d
  Large owner Ra Capital Management, L.P. sold $58,377,021 worth of shares (4,175,139 units at $13.98) (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 160d
  Director Gould Robert J sold $165,495 worth of shares (15,000 units at $11.03), decreasing direct ownership by 3% to 484,864 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Hill Colin

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Ezekowitz Alan

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Haviland Kate

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Dorton Katina

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Geraghty James A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director King Rachel K.

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Gould Robert J

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 304d
  SEC Form 4 filed by Director Banks Sonja

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 356d
  Principal Accounting Officer Tourangeau Greg sold $2,520 worth of shares (498 units at $5.06), decreasing direct ownership by 3% to 14,062 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 457d
  SEC Form 4 filed by Chief Financial Officer Musso Alan A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 457d
  SEC Form 4 filed by Chief Legal Officer Oltmans Curtis Gale

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 457d
  SEC Form 4 filed by Officer Sapir Alex

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 457d
  SEC Form 4 filed by Principal Accounting Officer Tourangeau Greg

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 532d
  SEC Form 4 filed by Director King Rachel K.

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 532d
  SEC Form 3 filed by new insider King Rachel K.

  3 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 584d
  New insider Ra Capital Management, L.P. claimed ownership of 10,229,099 shares (SEC Form 3)

  3 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 615d
  Large owner Ra Capital Management, L.P. disposed of 8,500,000 shares (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 661d
  Officer Sapir Alex exercised 150,000 shares at a strike of $3.27, increasing direct ownership by 346% to 193,360 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Ezekowitz Alan

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Gould Robert J

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Haviland Kate

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Banks Sonja

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Collins James J.

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Dorton Katina

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Geraghty James A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  SEC Form 4 filed by Director Hill Colin

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 681d
  New insider Hill Colin claimed no ownership of stock in the company (SEC Form 3)

  3 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 721d
  Tourangeau Greg sold $1,831 worth of shares (236 units at $7.76), decreasing direct ownership by 2% to 11,571 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 771d
  SEC Form 4 filed by Horn Patrick Taylor

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 771d
  New insider Horn Patrick Taylor claimed no ownership of stock in the company (SEC Form 3)

  3 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 783d
  Tourangeau Greg sold $57,219 worth of shares (4,884 units at $11.72), decreasing direct ownership by 29% to 11,807 units (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 786d
  Sapir Alex bought $492,028 worth of shares (43,360 units at $11.35) (SEC Form 4)

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 821d
  SEC Form 4 filed by Tourangeau Greg

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 821d
  SEC Form 4 filed by Musso Alan A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 821d
  SEC Form 4 filed by Oltmans Curtis Gale

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 832d
  SEC Form 4 filed by Musso Alan A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 995d
  SEC Form 4 filed by Musso Alan A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 995d
  SEC Form 3: New insider Musso Alan A claimed no ownership of stock in the company

  3 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1032d
  SEC Form 3 filed by new insider Sapir Alex

  3 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Geraghty James A

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Dorton Katina

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Banks Sonja

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Haviland Kate

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Ezekowitz Alan

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Gould Robert J

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1036d
  SEC Form 4 filed by Collins James J.

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1085d
  SEC Form 4 filed by Tourangeau Greg

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1098d
  SEC Form 4 filed by Hayes Melvin H. Iii

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1098d
  SEC Form 4 filed by Oltmans Curtis Gale

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)
• 1172d
  SEC Form 4 filed by Oltmans Curtis Gale

  4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)